On November 21st, 2023, Kris S. Choi, Head of Marketing & Business Development at ST Pharm, presented 'To Become a Global Korean CDMO' at the 2023 Economic Daily Pharmaceutical Bio Forum held at the National Assembly Library in Yeouido, Seoul. The event was co-organized by Myunghee Jo, a member of the National Assembly, and Economic Daily, a media company in Korea.
With 20 years of experience as Oligonucleotides CDMO business, Kris S. Choi addressed ST Pharm's challenging yet exciting journey in the Oligonucleotides CDMO, aiming to position as the 'Global top-3' Oligonucleotides CDMO.
He especially highlighted 'strong track record' and 'high-profile cGMP integrity' as qualifications for being recognized as a Global CDMO company.
ST Pharm has successfully got approval on cGMP inspections by global regulatory agencies, including the FDA, EDQM, ANVISA, PMDA, TGA, and HPRA since 2000s. Recently, in October 2023, the manufacturing facility at Banwol Campus also received FDA approval, and in 2022, it completed Pre-Approval Inspection (PAI) for cGMP oligonucleotides commercial manufacturing, marking a 1st in Asia.
He also addressed the consistent expansion and development of ST Pharm’s Oligonucleotides manufacturing facility. By completing the construction of the 2nd oligonucleotides facility by 2025, ST Pharm anticipates leaping to become a global CDMO company.
ST Pharm will continue to strive its best to contribute to the advancement and growth of a Global CMO and CDMO company in Korea.
LinkedIn
With 20 years of experience as Oligonucleotides CDMO business, Kris S. Choi addressed ST Pharm's challenging yet exciting journey in the Oligonucleotides CDMO, aiming to position as the 'Global top-3' Oligonucleotides CDMO.
He especially highlighted 'strong track record' and 'high-profile cGMP integrity' as qualifications for being recognized as a Global CDMO company.
ST Pharm has successfully got approval on cGMP inspections by global regulatory agencies, including the FDA, EDQM, ANVISA, PMDA, TGA, and HPRA since 2000s. Recently, in October 2023, the manufacturing facility at Banwol Campus also received FDA approval, and in 2022, it completed Pre-Approval Inspection (PAI) for cGMP oligonucleotides commercial manufacturing, marking a 1st in Asia.
He also addressed the consistent expansion and development of ST Pharm’s Oligonucleotides manufacturing facility. By completing the construction of the 2nd oligonucleotides facility by 2025, ST Pharm anticipates leaping to become a global CDMO company.
ST Pharm will continue to strive its best to contribute to the advancement and growth of a Global CMO and CDMO company in Korea.